3 completed. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
Follow AKB-9778: new trials by email Literature Review of AKB-9778 trials Research Report on AKB-9778
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR) AKB-9778, Placebo - Nonproliferative Diabetic Retinopathy | Phase 2 | Completed | EyePoint Pharmaceuticals, Inc. | 167 | 2017-06-09 | 2023-06-27 |
| Open Label Study to Assess the Efficacy and Safety of AKB-9778 in Subjects With Macular Edema Due to RVO AKB-9778 - Retinal Vein Occlusion | Phase 2 | Completed | Aerpio Therapeutics | 16 | 2015-01-01 | 2018-06-27 |
| The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema AKB-9778, ranibizumab, Placebo - Diabetic Macular Edema (DME) | Phase 2 | Completed | Aerpio Therapeutics | 144 | 2014-01-01 | 2017-03-16 |
Aerpio Therapeutics (2) · EyePoint Pharmaceuticals, Inc. (1)
United States (3)